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Abstract 
The aims of this study review were to: systematically identify the current evidence base of 
randomised controlled trials (RCTs) of spinal cord stimulation (SCS) placebo (or ‘sham’) 
trials for neuropathic pain and (2) to undertake a meta-analysis to investigate the 
effectiveness of SCS when compared with a placebo comparator arm. Electronic databases 
were searched from inception until January 2019 for RCTs of SCS using a placebo/sham 
control. Searches identified eight eligible placebo-controlled randomised trials of SCS for 
neuropathic pain. Meta-analysis shows a statistically significant reduction in pain intensity 
during the active stimulation treatment periods compared to the control treatment periods; 
pooled mean difference -1.15 (95% confidence interval -1.75 to -0.55, p=0.001) on a 10-point 
scale. Exploratory study level subgroup analysis suggests a larger treatment effect in RCTs 
using a placebo control (defined as studies where the device was inactive and at least one of 
the study procedures was different between the arms) than a sham control (defined as all 
study procedures being equal between arms including SCS device behaviour). Our findings 
demonstrate limited evidence that SCS is effective in r ducing pain intensity when compared 
to a placebo intervention. Our analyses suggest that he magnitude of treatment effect varies 
across trials and, in part, depends on the quality of patient blinding and minimisation of 
carryover effects. Improved reporting and further mthodological research is needed into 
placebo and blinding approaches in SCS trials. Furthermore, we introduce a differentiation 
between placebo and sham concepts that may be generalisable to trials evaluating surgical or 
medical procedures. 
 
Keywords: placebo; crossover randomised controlled trials; spinal cord stimulation; 
systematic review; meta-analysis 
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INTRODUCTION 
Spinal cord stimulation (SCS) is a recognised option for the management of chronic 
neuropathic pain with randomised controlled trials (RCTs) performed to investigate its 
effectiveness for conditions such as failed back surgery syndrome (FBSS),[25] complex 
regional pain syndrome (CRPS)[21] and painful diabetic neuropathy.[6] Conventional 
medical management has however been the comparator most commonly used in RCTs to date 
evaluating SCS for neuropathic pain. 
Reports have suggested that at least some part of pain relief observed at early stages of SCS 
therapy may be the result of a placebo effect with long-term follow-up revealing loss of 
efficacy for a proportion of participants when compared to the earlier primary endpoint.[9; 
20; 22; 26; 34] It is widely accepted that use of placebo or sham controls in a clinical trial can 
reduce the unblinding bias (knowing the treatment rceived) of patients, clinicians, and 
researchers can result in non-specific treatment effects reported by patients. The literature 
suggests that factors relating to patient expectation of treatment success are central in the 
development of the placebo response; these are highly relevant in SCS use.[52] 
In the last decade, several RCTs have evaluated SCS for neuropathic pain conditions when 
compared to a placebo arm. These RCTs have been possible due to the emergence of new 
sensation-free SCS modalities such as burst, high frequency or high density. Despite 
difficulties with blinding, conventional or paraesthesia producing SCS has been compared to 
placebo in a number of small studies with varied results, including the effects of placebo 
stimulation being similar to those of active treatments.[1; 37]  
In our context ‘placebo trials’ are trials that specifically set out to select a comparator to ‘find 
out’ what might be the placebo effect of the active int rvention e.g. RCT of low dose SCS vs 
traditional SCS (both groups get implant, etc). However, as we know, in this design there is 
high likelihood that patients will be aware of their allocation and therefore the design is 
effectively ‘open label’. Within this framework, we could therefore define ‘sham trials’ as a 
specific subgroup of placebo trials where there is the possibility to ‘fully blind’ patients, 
clinicians and researchers. In the neuromodulation setting this would need to be an active 
intervention vs comparator that is completely paraesth sia free e.g. RCT of HF10 vs no 
stimulation. Given the complexities in enabling a sh m for a treatment such as SCS and for 
the purposes of this review, sham was defined as a control where all study procedures were 
equal between arms including implantable pulse generator (IPG) behaviour (i.e. need for 
recharging). Placebo was defined as a control where t  IPG was inactive and at least one of 
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the study procedures was different between the arms(i.e. no IPG spontaneous discharge, i.e. 
built-in current leak), admitting overtly the possibility of unblinding. 
We have recently conducted a systematic review that focused on the methodological facets of 
randomised placebo-controlled trials of SCS.[10] The aim of this systematic review was to 
investigate the effectiveness of SCS for patients with neuropathic pain when compared with a 
placebo comparator arm. 
 
METHODS 
The systematic review methods followed the general principles outlined in the Centre for 
Reviews and Dissemination (CRD) guidance for conducting reviews in health care.[3] This 
systematic review is reported in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA).[31] The protocol for this review is 
registered on PROSPERO as CRD42018090412. The current review focuses on the 
effectiveness results of SCS placebo-controlled trials in patients with neuropathic pain. 
 
Search strategy 
Electronic databases MEDLINE, CENTRAL, EMBASE and WikiStim were initially 
searched from inception until February 2018 and updated on the 29th January 2019. The 
search strategies were designed using a combination of both indexing and free text terms with 
no restriction on language. The search strategy used for the MEDLINE database is presented 
in Supplementary material 1 of this manuscript (avail ble at 
http://links.lww.com/PAIN/A868). The MEDLINE search strategy was adapted to enable 
similar searches of the other relevant electronic databases. The reference lists of relevant 
systematic reviews and eligible studies were hand-searched to identify further potentially 
relevant studies. 
 
Study selection 
The citations identified were assessed for inclusion in the review using a two stage process. 
First, two reviewers independently screened all the ti les and abstracts identified by the 
electronic searches to identify the potentially relevant articles to be retrieved. Second, full-
text copies of these studies were obtained and assessed independently by two reviewers for 
inclusion using the eligibility criteria outlined in Table 1. Any disagreements were resolved 
through discussion at each stage, and, if necessary, in consultation with a third reviewer. 
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[Insert Table 1 here] 
 
Data extraction 
A data extraction form was designed to enable data extr ction relating to study author and 
year of publication, country where the study was conducted, study design, population, 
number of participants included in the analysis, intervention including frequency of 
stimulation (if reported), details on placebo or sham comparator, duration of placebo or sham, 
consideration of carryover effect and washout periods (for cross-over RCTs only) and 
efficacy outcomes assessed. 
Data extraction was performed by one reviewer and checked for accuracy by a second 
reviewer. Any disagreements were resolved through discussion, and, if necessary, in 
consultation with a third reviewer. 
 
Risk of bias assessment 
We planned to assess risk of bias by using the revised Cochrane risk of bias tool (RoB 2.0) 
appropriate to the study design of the included trials. All the studies that met the eligibility 
criteria were cross-over trials. Therefore we used th  RoB 2.0 specific for cross-over 
trials.[17] Risk of bias assessment of the included stu ies was undertaken by one reviewer 
and checked by a second reviewer. Any disagreements were resolved by discussion, and, if 
necessary, in consultation with a third reviewer. 
 
Data synthesis 
Our primary efficacy outcome was pain, reported on a validated scale such as visual analogue 
scale (VAS; 0 to 10 cm or 0 to 100 mm) or numeric rating scale (NRS; 0 to 10). To 
standardise to a single scale, we assumed that VAS (0 to 10 cm) and NRS (0 to 10) were 
equivalent and we converted VAS (0 to 100mm) by dividing pain scores by 10. 
The measure of treatment effect for data synthesis was the mean difference and standard error 
of the mean difference between active stimulation and control, to be pooled via the generic 
inverse variance method of meta-analysis.[7] 
For cross-over studies, we intended to extract in the first instance, the mean difference in pain 
scores between treatment periods and a measure of pcision which takes account of the 
paired nature of the data.[14] If such data were not reported, or if we were concerned 
regarding carry-over effect across treatment periods, we would have extracted the mean pain 
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score and a measure of precision for the first tream nt period only and treated these data as a 
parallel study in data synthesis. 
Four included cross-over studies reported data only f r the pain scores at the end of all 
treatment periods (i.e. the mean pain score and staard deviation of all participants during 
that treatment period). The results do not reflect the paired (correlated) nature of the data and 
if used in meta-analysis, would overestimate the variance of the pooled result. We received 
partial individual participant data for one study[37] and used these data to estimate a within-
participant correlation value between treatment periods of 0.517. We were then able to 
calculate the mean difference and the standard error of the mean difference taking account of 
the correlated structure of the data using the formulae described in the Appendix of Elbourne 
et al.[14] 
We were also able to extract individual participant da a for 10 participants in one study[55] 
and used these data to estimate a within-participant correlation value between treatment 
periods of 0.963. We repeated all data synthesis using this correlation value to calculate the 
mean difference and the standard error of the mean difference. Numerical results of meta-
analysis were similar and conclusions were unchanged (results not shown, available on 
request from corresponding author). 
Three of the cross-over studies with mean difference and associated standard error adjusted 
for the paired design included more than one active treatment period and a sham or placebo 
[2] treatment period. To allow comparisons for each of the active treatments to the control 
treatment period to be included in meta-analysis without multiple counting of the control 
treatment period, we divided the number of participants included in the study by the number 
of comparisons when calculating the mean difference and associated standard error. 
 
Assessment of heterogeneity and subgroup analysis 
We assessed the level of heterogeneity present between trials by visual inspection of forest 
plots and formally according to the I2 statistic (the percentage of variability between trials 
that is due to statistical heterogeneity). We anticipated that clinical heterogeneity would be 
present in analysis due to differences in study design and participant characteristics, therefore 
we performed a random-effects meta-analysis.[7] 
We also performed subgroup analysis to further investigate statistical heterogeneity; we 
assessed the duration of treatment (subgroups of 1 to 4 weeks) and type of control (sham, 
placebo or other). Subgroup meta-analyses were also perf rmed with random-effects due to 
anticipated heterogeneity between studies. We did not formally test for differences between 
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subgroups; rather we interpreted any visual differences in the pooled results across 
subgroups. 
 
RESULTS 
Study selection 
The searches resulted in the identification of 1473 citations. After the removal of duplicate 
records, we identified 1309 potential citations. Following initial screening of titles and 
abstracts, 35 publications were considered to be pot ntially relevant and were retrieved to 
allow assessment of the full-text publication. After r view of the full-text publications, 8 
studies were included in the review.[1; 5; 24; 30; 7; 42; 49; 55] Twenty-seven studies were 
excluded at the full-text paper screening stage because the comparator was not a placebo or 
sham neurostimulation.[4; 6; 8; 9; 13; 18; 19; 21; 3; 25; 28; 32-35; 41; 43-48; 50; 51; 53; 
54; 57] The PRISMA flow chart detailing the screening process for the review is shown in 
Figure 1. 
 
[Insert Figure 1 here] 
 
Characteristics of included studies 
The characteristics of the eight included studies ar  summarised in Table 2. All the included 
studies were cross-over RCTs.[1; 5; 24; 30; 37; 42; 49; 55] Four studies restricted the 
participants to a specific condition such as FBSS[1; 37; 42] or CRPS.[24] Four studies 
included participants with a range of conditions.[5; 30; 49; 55] 
The type of stimulation investigated in the studies included paraesthesia inducing, 
subthreshold, burst and high frequency SCS. Two studies included patients new to SCS (i.e. 
study was carried out immediately after implantation of the device).[1; 5] One of the studies 
with patients new to SCS involved a trial period conducted with an external IPG system via 
externalised extension wires. Participants who completed the 28-day period of external 
stimulation then underwent permanent implantation of the SCS device.[5] The remaining six 
studies included patients already receiving paraesthesia stimulation for at least four weeks 
before enrolment in the trial.[24; 30; 37; 42; 49; 55] The phases (i.e. different settings) in the 
cross-over RCTs ranged from two to five phases. The duration of each phase ranged from 
one week in three studies [5; 42; 55] to three weeks in one study.[1] One study included only 
a 12 hour interval before quantitative sensory testing (QST) assessment.[30] The duration of 
each cross-over phase was two weeks in three studie.[24; 37; 49] Four of the studies did not 
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consider a carryover effect or washout period betwen the different stimulation phases.[1; 5; 
42; 55] In the studies that included a washout period, this period consisted of 12 hours,[30] 
two days [24] or a two week washout period with their own paraesthesia stimulation.[37; 49] 
 
[Insert Table 2 here] 
 
Risk of bias assessment 
The summary of the risk of bias assessment is present d in Table 3. The full assessment for 
each included study is presented in Supplementary mterial 2 (available at 
http://links.lww.com/PAIN/A868). Four studies were judged to have some concerns for the 
randomisation domain, as no information was presented about how the sequence was 
generated or concealed.[5; 30; 49; 55] Although some studies included an intervention arm 
where patients would feel paraesthesias [24; 30] and therefore would not be blind to 
intervention, other studies [30; 42; 55] were judge to have a high risk of bias due to the 
possibility of a carryover effect (domain deviations from intended interventions). No 
information was presented in Tjepkema-Cloostermans et al[49] besides stating that the study 
was double-blind; therefore, it was judged as presenting some concerns of bias for the 
domain deviations from intended interventions. Four st dies reported only information on 
patients that received the interventions and provided ata at all assessment times (per 
protocol analysis) or did not report how many patients were initially randomised.[1; 30; 37; 
55] Therefore, it was considered there were some concerns of bias for the missing outcome 
data domain. There were some concerns of bias for the measurement of the outcome domain 
in four studies as outcome assessors were aware of th intervention received by study 
participants or no information was provided.[5; 24;30  49] One study did not carry out 
statistical analysis appropriate for a cross-over design,[42] while another study did not report 
any analysis methods.[5] There were some concerns with selective reporting in the studies by 
Al-Kaisy et al,[1] De Ridder et al[5] and Kriek et al.[24] The numerical results were provided 
only for statistically significant results. This omission includes test for carryover effect which 
was not presented because it was not statistically significant.[1] It was considered that there 
were some concerns of bias regarding the selection of the reported result domain for these 
three studies. Overall bias of included studies ranged from some concerns to high risk of bias. 
None of the studies was considered to have a low risk of overall bias. 
 
[Insert Table 3 here]  
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Outcomes of included studies 
Pain outcomes, treatment satisfaction and patient stimulation preferences for all included 
studies are presented in Table 4. 
Twelve comparisons of an active stimulation and control treatment period, including 155 
participants from six cross-over studies could be pooled in meta-analysis to investigate the 
effect on pain intensity (Figure 2). We were unable to include any numerical results for two 
studies recruiting 30 participants within meta-analysis[5; 30] due to inadequate numerical 
data presented within the trial journal publications. Meta-analysis shows a statistically 
significant reduction in pain intensity (VAS 0 to 10cm or NRS 0 to 10) during the active 
stimulation treatment periods compared to the control treatment periods; pooled mean 
difference -1.15 (95% confidence interval [CI]: -1.75 to -0.55, p=0.001). There was a 
substantial amount of heterogeneity present between the comparisons (I2 =65.8%). 
 
[Insert Table 4 here] 
 
[Insert Figure 2 here] 
 
Subgroup analyses 
We performed subgroup analysis to further investigate the duration of treatment (subgroups 
of 1 to 4 weeks) and type of control (sham, placebo or ther) on the treatment effect. 
Two studies had treatment periods of one week,[42; 55] two studies had treatment periods of 
two weeks,[37; 49] one study had treatment periods of three weeks[1] and one study had 
treatment periods of four weeks.[24] Subgroup analysis by duration of treatment shows no 
clear differences in treatment effect according to the duration of the stimulation and control 
treatment period (Figure 3). Duration of treatment is relevant particularly in respect of timing 
of pain data collection where some investigators have chosen to collect data only during the 
last three days of the period[1; 37] in order to mini ise the impact of any carryover effect 
from the previous period. 
 
[Insert Figure 3 here] 
 
Two studies used a sham control,[1; 37] three studies used a placebo control[24; 42; 55] and 
one study used low amplitude burst stimulation as the control treatment (Figure 4).[49] 
Subgroup analysis by type of control shows that the treatment effect of stimulation compared 
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to control appears much larger in the studies using placebo control (pooled MD, -1.88, 95% 
CI -2.77 to -0.98) than the studies using sham control – IPG behaviour equal in all arms i.e. 
need for recharging (pooled MD, -0.34, 95% CI -1.04 to 0.36) and the study using low 
amplitude burst stimulation (MD -0.20, 95% CI -1.01 to 0.61). However, a substantial 
amount of heterogeneity remains between the studies sing placebo control (I2=65.2%). 
 
[Insert Figure 4 here] 
 
DISCUSSION 
To our knowledge this is the first systematic review of randomised placebo (‘sham’) 
controlled trials of SCS for neuropathic pain. Our meta-analysis of six cross-over studies and 
a total of 155 participants has shown an average reduction in pain intensity (VAS 0 to 10cm 
or NRS 0 to 10) during the active stimulation treatment periods compared to the control 
treatment periods of -1.15 (95% CI: -1.75 to -0.55, p=0.001). The substantial statistical 
heterogeneity in effect across trials may be partly explained by the type of control. 
Exploratory subgroup analysis by type of control shows that the treatment effect of 
stimulation compared was larger in the studies using placebo control[24; 42; 55] than the 
studies using sham control.[1; 37]. We defined sham as a control when all study procedures 
were equal between arms including IPG behaviour (i.e. need for recharging) as opposed to 
placebo where the IPG was inactive and at least one of the study procedures was different 
between the arms (i.e. no spontaneous IPG discharge, i.e. no current leak). Presumably a 
sham control is more plausible to participants and would be associated with a smaller 
potential of unblinding particularly where the participants have prior experience with SCS. 
Accidental unblinding during the placebo phase might reduce the impact of the placebo arm 
and consequently inflate the effect of the active int rvention. However, included studies were 
generally poorly reported and had methodological limitations related to quality of blinding 
and handling of carryover effects due to cross-over designs. 
Despite limiting the scope of our review to subjects with neuropathic pain, we found a great 
deal of variation in pain conditions between the studies which varied from FBSS to general 
neuropathic pain with a range of conditions. Furthermore, the type of stimulation investigated 
included a wide range of modalities such as paraesthesia stimulation, subthreshold, burst and 
varying kilohertz frequencies up to 5880 Hz. In addition, the determination of the perception 
threshold in studies using subthreshold stimulation has been carried out in variable positions 
with a number of studies not reporting how the thres old was measured. Perceptual threshold 
AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2019
9 
 
for conventional paraesthesia-based SCS varies by about 25% with simple postural changes, 
and this could easily lead to unblinding.[36] No study has yet evaluated the 10kHz frequency 
against a sham control. 
All eight included studies employed a cross-over design with most including a number of 
treatment phases. In order to conduct a pairwise comparison of placebo versus various modes 
of stimulation the study populations were divided into pairwise comparisons and our 
statistical analysis was adjusted accordingly to take ccount of these different comparisons. 
The use of a cross-over design with a number of stimulation parameters and periods 
generates a risk of a carryover effect of active modes of stimulation spilling onto the placebo 
period. We note that, investigators employed various strategies to address the carryover issue 
such as including a washout period varying from 12 hours[30] to two weeks[49] or collecting 
outcomes at the end of the crossover period.[1; 37] However, we consider that despite these 
mitigating strategies estimating the impact of any carryover remains difficult to quantify. 
Indeed, in experimental animals, the duration of neuronal inhibition and pain relief by SCS 
often exceeds the stimulation period.[15; 29] These findings are consistent with clinical 
observations that analgesia not only occurs during the SCS, but also often outlasts the period 
of SCS.[16] In a study looking at intermittent versus continuous conventional SCS, Wolter 
and Winkelmüller suggest that in the majority of patients a clinically significant carryover 
effect is demonstrable during 90 minutes or less.[56] While clinical experience suggests the 
wash-out (as well as the wash-in) time is influenced both by the diagnosis and the stimulation 
mode, the fact remains that no reliable data on the duration of carryover effect are available. 
Therefore, it remains possible that the overall placebo effect in our meta-analysis has been 
increased by the carryover effect from active stimulation. 
Only two studies examined the impact of the “period effect” or the order of the treatment 
introduction on outcomes. Perruchoud et al[37] concluded that the first treatment introduced 
produced the highest impact regardless of whether i was sham or active treatment; in 
contrast Al-Kaisy et al[1] found no period effect in their study. 
Another factor which may impact the magnitude of the response to a placebo device in the 
studies is the plausibility of the sham control or inactive device. A sham/placebo control may 
be more plausible in de novo patients who lack famili rity with the functioning of an SCS 
device and have limited knowledge of the handheld controller and no clear estimate of the 
recharging period following a particular mode of stimulation. In contrast participants with 
long experience of SCS require a more robust placebo due to their ability to unmask a 
placebo device particularly where the recharging duration is drastically reduced.  
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Only two of the eight studies recruited de novo participants.[1; 5] The De Ridder study[5] 
was conducted entirely during the screening trial period where attitudes and expectations may 
differ from following an IPG implant.[40] Al-Kaisy et al used de novo patients as well as a 
robust placebo control including a controlled current l ak from a rechargeable IPG; no 
handheld patient controller was issued throughout the s udy.[1] As such in this study two of 
the three frequencies tested produced pain relief that was not significantly different from 
placebo stimulation. In contrast, in the study by Kriek et al, the information on the placebo 
used is limited to “Programming placebo was performed with a 100-Hz stimulus to maintain 
an equal programming paradigm and sensation for the pati nt. However, the IPG was 
switched off immediately after ‘programming’ placebo stimulation and remained switched 
off during the coming 2- week test period.”[24] Since the study tested high frequency as well 
as burst it is safe to assume that the participants were implanted with a rechargeable IPG. We 
however, found no reference in the manuscript to either the IPG being programmed to 
produce a current leak in the placebo phase nor could we find a clear indication of what 
arrangements were made to prevent accidental unblinding during the placebo phase based on 
a sudden reduction of need for recharging.  
Apart from a single study that favoured placebo stimulation all other studies favoured the test 
stimulation mode. However, the pain intensity forest plot needs to be interpreted with 
caution, for while the Perruchoud et al study found no significant statistical or clinical 
difference between 5kHz stimulation and sham, it remains a fact that in the study 5kHz 
stimulation was better than placebo by a margin of 11% on the primary outcome 
measure.[37] Yet it may be argued that the electrodes were positioned to obtain the best 
overlapping paraesthesia rather than targeting Th9-Th10 level. In contrast the study of 
Tjepkema-Cloostermans found burst as well as low burst to be better than conventional 
stimulation.[49] Since the authors had initially con eived low burst as a placebo control these 
results are difficult to interpret. 
Some of the studies included did not present a power calculation.[5; 30; 49] Considering the 
IMMPACT recommendation [11] of detection of ≥2.0 point pain difference in VAS/NRS 
between groups (and assuming a typical standard deviation of 2.5, 20% attrition and 90% 
power) a parallel group design study would need a total of ≥84 patients (42 per arm) and a 
cross-over design (with conservative assumption of o within correlation between pre and 
post VAS/NRS) would need a total of ≥24 patients. Four of the studies included were 
therefore not adequately powered at 90% level to deect differences in pain intensity between 
the groups. [5; 30; 42; 55] 
CC
EP
TE
D
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2019
11 
 
 
Strengths and weaknesses 
We believe this to be the first systematic review and meta-analysis of placebo-controlled 
trials of SCS in neuropathic pain. A focused eligibility criteria attempted to minimise the 
heterogeneity observed. The review process, including study identification, selection and data 
extraction, was carried out in line with PRISMA[31] and CRD guidance.[3] The review seeks 
to provide clarity and direction in reporting and methods in placebo (or sham) controlled 
trials in SCS, that may well have relevance to the broader field of neuromodulation trials. 
The review cites a limited number of RCTs, none of which judged as having a low risk of 
bias. All of the studies employed a cross-over design in which each participant served as their 
own control, which can increase the statistical power of the study. Nonetheless, all of the 
included studies enrolled small sample sizes ranging from 10 to 40 participants, and while all 
the studies compared some form of SCS to sham, none used the same SCS comparator. The 
small study size, differing SCS modalities and differ ng control setups may explain the 
heterogeneity observed. 
We were unable to include any numerical results for tw  studies recruiting 30 participants 
within meta-analysis[5; 30] due to inadequate numerical data provided in the publications. 
Furthermore, numerical results presented in four of the studies[1; 24; 42; 49] included in the 
meta-analysis were only suitable after our statistical adjustment for the within-patient 
correlation inherent to the cross-over design. 
While we were aware of a number of RCTs comparing SCS to placebo in refractory 
angina,[12; 27; 58] we decided to limit the scope of our review to the trials recruiting 
participants with neuropathic pain due to the use of different outcome measures as well as the 
use of a parallel trial design in one of the studies. 
 
CONCLUSION 
In conclusion, the findings of this systematic review show that use of SCS leads to a decrease 
in pain intensity when compared to a placebo intervention. Nevertheless, exploratory sub-
group suggest that the magnitude of treatment effect varies across trials and depends on 
methodological characteristics including quality of patient blinding and minimisation of 
carryover effects. No studies have been identified assessing SCS at 10kHz versus placebo. 
Further research is needed to evaluate the ‘true’ eff ct of SCS in decreasing pain intensity of 
patients with neuropathic pain. The differentiation between placebo and sham concepts 
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introduced in this paper merit further investigation n reviews and meta-analysis of trials 
evaluating surgical or medical procedures. 
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FIGURE LEGENDS 
 
Figure 1 PRISMA flow chart 
 
Figure 2. Meta-analysis of pain intensity comparing active SCS stimulation to control 
Note: Al-Kaisy 2018, Kriek 2017 and Schu 2014 included more than one active treatment period and 
a control treatment period. To allow each active treatment period to be compared to the control 
treatment in meta-analysis, we divided the number of participants included in the study by the number 
of comparisons when calculating the mean difference and associated standard error. In other words, 
eight participants contributed to each comparison in Al-Kaisy 2018, seven participants in Kriek 2017 
and ten participants in Schu 2014. 
 
Figure 3. Subgroup meta-analysis of pain intensity comparing active SCS stimulation to 
control, by duration of control (weeks) 
Note: See footnote of Figure 2 for a description of the comparisons made from Al-Kaisy 2018, Kriek 
2017 and Schu 2014 
 
Figure 4. Subgroup meta-analysis of pain intensity comparing active SCS stimulation to 
control, by type of control 
Note: See footnote of Figure 2 for a description of the comparisons made from Al-Kaisy 2018, Kriek 
2017 and Schu 2014 
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Table 1 Eligibility criteria 
Inclusion criteria (if all of the following met) Exclusion criteria (if any of the following 
met) 
1. Population comprised patients with 
neuropathic pain 
1. Neurostimulation intervention other than SCS 
2. Intervention was SCS (all stimulation 
protocols) 
2. Comparator only included an alternative 
active stimulation protocol or a non-
neurostimulation control 
3. Comparator was placebo 3. Design/protocol paper, m thodological paper, 
(systematic) review, meta-analysis, 
commentaries/editorial 
4. Study design was an RCT (parallel or cross-
over) 
4. Insufficient information (e.g. study only 
available as a conference proceeding/abstract) 
RCT=randomised controlled trial; SCS=spinal cord stimulation 
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Table 2 Characteristics of randomised controlled trials included in the systematic review 
Author 
(year) 
Study design* Number in 
analysis 
and age ± 
SD 
Intervention Control Phase and overall 
study duration 
Carryover effect Outcomes 
Al-Kaisy 
(2018)[1] 
Cross-over (3 
active treatment 
periods and 1 
sham treatment 
period) 
24 (M=16; 
F=8) 
 
47.9 years 
(range 33 to 
60) 
1200 Hz, 
3030 Hz, and 
5882 Hz 
Sham (IPG turned on and 
discharging, but without 
electricity transmitted to the 
lead) 
3 weeks (12 week cross-
over with 4 
phases/different settings) 
No significant carryover 
(no numbers presented) 
Pain (VAS 0 to 10cm) in back 
and leg, treatment satisfaction, 
PGIC 
De Ridder 
(2013)[5] 
Cross-over (2 
active treatment 
periods and 1 
placebo treatment 
period) 
15 (M=4; 
F=11) 
 
54 years 
(range 39 to 
68) 
Burst and 
paraesthesia 
stimulation 
(40 or 50 Hz) 
Placebo (Burst stimulation was 
applied on the predefined 
electrode contacts until the 
patient experienced 
paraesthesia. Subsequently 
the stimulator intensity was 
decreased like in burst 
programming but continued 
until zero amplitude) 
1 week (3 week cross-
over with 3 
phases/different settings) 
No significant carryover 
(no numbers presented) 
Pain (VAS 0 to 100mm) - limb, 
back and general pain. Pain 
vigilance and awareness 
questionnaire, treatment 
preference. Paraesthesias 
caused by the stimulation 
Kriek 
(2017)[24] 
Cross-over (4 
active treatment 
periods and 1 
placebo treatment 
period) 
29 (M=4; 
F=25) 
 
42.55 ± 12.83 
years 
40 Hz, 500 
Hz, 1200 Hz 
and burst 
Placebo (Programming was 
performed with a 100 Hz 
stimulus to maintain an equal 
programming paradigm and 
sensation for the patient. The 
IPG was switched off 
immediately after programming 
and remained switched off 
during the 2 week test period) 
2 weeks (10 week cross-
over with 5 
phases/different settings) 
Washout and no 
significant carryover (pain 
scores at the start of each 
period measured) 
Pain (VAS 0 to 100mm), MPQ, 
Global Perceived Effect, patient 
preference of treatment setting 
Meier 
(2015)[30] 
Cross-over (1 
active treatment 
period and 1 
deactivated 
treatment period) 
14 (M=5; F=9) 
 
53 years 
(median) 
Paraesthesia 
stimulation 
Placebo (Device switched off) 12 hours (2 day cross-
over with 2 
phases/different settings) 
Washout, carryover not 
measured but may have 
impacted on results 
QST; mechanical thresholds, 
thermal thresholds, wind-up 
like pain, pain (NRS 0 to 10 
cm), areas of painful symptoms 
Perruchoud 
(2013)[37] 
Cross-over (1 
active treatment 
period and 1 
sham treatment 
period) 
33 (M=16; 
F=17) 
 
54.2 ± 10.7 
HF at 5 kHz Sham (Programming occurred 
as for HF. The stimulator was 
switched off after completing 
programming and current leak 
programmed during the sham 
2 weeks (8 week cross-
over with 2 
phases/different settings; 
before and after the first 
HF or sham phase there 
Washout but highly 
significant period effect 
reported 
PGIC, pain (VAS 0 to 100 mm), 
and quality of life (EQ-5D) 
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years periods) was a 2 week period with 
paraesthesia SCS) 
Schu 
(2014)[42] 
Cross-over (2 
active treatment 
periods and 1 
placebo treatment 
period) 
20 (M=7; 
F=13) 
 
58.6 ± 10.2 
years 
Subthreshold 
(500 Hz) and 
burst 
Placebo (No stimulation was 
programmed; device switched 
off) 
1 week (3 week cross-
over with 3 
phases/different settings) 
No washout, stated that 
carryover may have 
impacted on the results 
Pain (NRS, 0 to 10 cm), pain 
quality - SFMPQ, safety, pain 
related disability - ODI, patient 
stimulation preference 
Tjepkema-
Cloostermans 
(2016)[49] 
Cross-over (1 
active high 
stimulation 
treatment period 
and 1 control low 
stimulation 
treatment period) 
40 (M=24; 
F=16) 
 
58 years 
(range 41 to 
73) 
Burst Low amplitude burst (0.1 mA 
bursts) 
2 week (6 week cross-
over with 2 
phases/different settings; 
2 week period with 
paraesthesia SCS 
between the 2 different 
settings) 
Washout and no 
significant carryover (p 
value of period effect 
presented) 
Pain (VAS 0 to 100mm), quality 
of life (MPQ), patient 
preference, proportion of 
patients with 30% extra pain 
reduction as compared with 
paraesthesia stimulation 
Wolter 
(2012)[55] 
Cross-over (1 
active sub-
threshold 
stimulation 
treatment period 
and 1 no 
stimulation 
treatment period) 
10 (M=6; F=4) 
 
54 ± 6.2 years 
Subthreshold Placebo (Device switched off) 1 week (2 week cross-
over with 2 
phases/different settings) 
Not mentioned Pain (NRS 0 to 10 cm), HADS, 
PDI and BDI 
BDI=Beck depression inventory; F=female; HADS=hospital anxiety and depression score; HF=high frequency; IPG=implantable pulse generator; M=male; MPQ=McGill pain questionnaire; 
NRS=numerical rating scale; ODI=Oswestry disability index; PDI=pain disability index; PGIC=patient’s global impression of change; QST=quantitative sensory testing; SD=standard deviation; 
SFMPQ=short-form McGill pain questionnaire; VAS=visual analogue scale 
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Table 3 Risk of bias assessment 
Author (year) 
Randomisation 
process 
Deviations from 
intended 
interventions 
Missing 
outcome data 
Measurement of 
the outcome 
Selection of the 
reported result Overall Bias 
Al-Kaisy (2018)[1] Low Low Some concerns Low Some concerns Some concerns 
De Ridder (2013)[5] Some concerns Low Low Some concerns Some concerns Some concerns 
Kriek (2017)[24] Low Low Some concerns Some concerns Some concerns Some concerns 
Meier (2015)[30] Some concerns High Some concerns Some concerns Low High 
Perruchoud (2013)[37] Low Low Some concerns Low Low Some concerns 
Schu (2014)[42] Low High Low Low Low High 
Tjepkema-Cloostermans (2016)[49] Some concerns Some concerns Low Some concerns Low Some concerns 
Wolter (2012)[55] Some concerns High Some concerns Low Low High 
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Table 4 Pain outcomes and treatment satisfaction / patient stimulation preferences 
Author 
(year) 
Pain intensity (VAS or NRS) Other pain measures Treatment satisfaction / patient stimulation 
preference 
Al-Kaisy 
(2018)[1] 
Mean low back pain scores were 4.83, 4.51, 4.57, and 
3.22, for sham, 1200 Hz, 3030 Hz, and 5882 Hz, 
respectively, p=0.002 
The mean leg pain scores were 3.06, 2.51, 2.37, 2.20, 
and 1.81, for baseline, sham, 1200 Hz, 3030 Hz, and 
5882 Hz, respectively, p=0.367 
PGIC - Statistically significant difference on 
subject scores among the frequency groups 
(p= 0.007), with more of those on sham 
reporting no change and more on 5882 Hz 
reporting considerable improvement 
There were 63%, 63%, 75%, and 75% who were either 
very satisfied or somewhat satisfied with the therapy, in 
the sham, 1200 Hz, 3030 Hz, and 5882 Hz group, 
respectively, p=0.672 
12 month open label phase - 29% of subjects elected to 
use 5882 Hz, 25% reverted to traditional stimulation, 21% 
and 12.5% chose either the 1200 Hz or the 3030 Hz 
setting, respectively, while 12.5% requested sham 
stimulation 
De Ridder 
(2013)[5] 
A comparison between placebo, paraesthesia 
inducing, and burst stimulation over back pain, limb 
pain, and general pain revealed an overall significant 
effect (F=4.31, p<0.05). Burst stimulation significantly 
differs from placebo stimulation for back pain, limb 
pain, and general pain, For back pain, no significant 
effect was obtained between paraesthesia inducing 
and placebo stimulation. However, analysis yielded a 
significant effect between paraesthesia inducing and 
placebo for limb pain and general pain 
NR After 4 weeks, patients were asked which stimulation 
design they preferred: all patients preferred burst mode. 
No patient indicated that paraesthesia inducing stimulation 
was unbearable 
Kriek 
(2017)[24] 
Mean pain scores were 39.83, 40.13, 42.89, 47.98, 
63.74 for paraesthesia inducing, 500 Hz, 1200 Hz, 
burst and placebo, respectively, p<0.001 
MPQ – average pain scores were 4.70, 
5.10, 5.31, 5.66, 7.07 for paraesthesia 
inducing, 500 Hz, 1200 Hz, burst and 
placebo, respectively, p<0.001 
14 (48%) preferred the paraesthesia inducing (40 Hz) 
frequency stimulation and 15 (52%) preferred one of the 
non-standard stimulation modalities 
Meier 
(2015)[30] 
Median pain scores were similar during SCS activated 
(4.5 [IQR, 3 to 6]) and SCS deactivated (4.5 [IQR, 3 to 
8]) 
Wind-up like pain - no statistical differences 
were found between the QST sessions 
NR 
Perruchoud 
(2013)[37] 
Adjusted for baseline pain VAS (under normal 
stimulation), the mean pain VAS on sham was 4.26 
vs. 4.35 on HF; the difference (HF minus sham) =-
0.09 (95% CI, -0.68 to 0.86; p=0.82). 
PGIC - There was a statistically significant 
“period effect,” whereby 51.5% (17/33) of 
patients improved at visit 3 and only 21.2% 
(7/33) at visit 5, irrespective of treatment 
received (mean difference in proportions = 
30.3%; 9–51%; p=0.006) 
The overall proportion of patients responding to HF 
stimulation was 42.4% (14/33 patients) vs. 30.3% (10/33 
patients) in the sham condition AC
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Schu 
(2014)[42] 
Mean pain scores were 5.6, 7.1, 4.7, 8.3 for 500 Hz, 
burst and placebo, respectively, F2,57=19.07, 
p<0.0001 
SFMPQ – mean scores were 25, 28.6, 19.5, 
33.5 for paraesthesia stimulation, 500 Hz, 
burst and placebo, respectively, F2,57=8.64, 
p=0.0005) 
Burst stimulation was preferred by 16 patients (80%), 500-
Hz stimulation by two patients (10%), and paraesthesia 
stimulation (baseline) by two patients (10%). None of the 
patients preferred placebo stimulation 
Tjepkema-
Cloostermans 
(2016)[49] 
Mean pain scores were 52, 42, 40 for paraesthesia 
stimulation, low burst and high burst, respectively, 
p=0.012 
PRI – mean scores were 20.4, 19.7, 18 for 
paraesthesia stimulation, low burst and high 
burst, respectively, p=0.34 
Eleven patients preferred paraesthesia stimulation, 15 
preferred high amplitude burst and 14 preferred low 
amplitude burst SCS 
Wolter 
(2012)[55] 
Mean pain scores were 3.6, 5.6, 6.4 for paraesthesia 
stimulation, subthreshold and no stimulation, 
respectively. Paraesthesia inducing vs subthreshold, 
p=0.0059; subthreshold vs no stimulation, p= 0.0020; 
paraesthesia inducing vs no stimulation, p=0.0020 
PDI -mean scores ranged from 3.8 (item 
‘vitally indispensable activities’) to 6.3 (item 
‘professional activities’); scores not 
presented by type of stimulation 
NR 
HF=high frequency; IQR=interquartile range; MPQ=McGill pain questionnaire; NR=not reported; NRS=numerical rating scale; QST=quantitative sensory testing; PDI=pain disability index; 
PGIC=patient’s global impression of change; PRI=pain rating index; QST=quantitative sensory testing; SCS=spinal cord stimulation; SFMPQ=short-form McGill pain questionnaire VAS=visual 
analogue scale 
 
AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2019
 
AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2019
 
AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2019
 
AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2019
 
AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2019
